Kymera Therapeutics, Inc.(KYMR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KYMR Kymera Therapeutics, Inc.

交易中 02-27 15:30:24 EST

90.86

-4.17

-4.39%

最高93.99	最低88.80	成交量61.68万
今开92.14	昨收95.03	日振幅5.46%
总市值74.18亿	流通市值49.63亿	总股本8,164万
成交额5,581万	换手率1.13%	流通股本5,463万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KYMR","market":"US","secType":"STK","nameCN":"Kymera Therapeutics, Inc.","latestPrice":90.86,"timestamp":1772224217047,"preClose":95.03,"halted":0,"volume":616753,"delay":0,"changeRate":-0.04388087972219301,"floatShares":54626600,"shares":81642394,"eps":-3.597465,"marketStatus":"交易中","change":-4.17,"latestTime":"02-27 15:30:24 EST","open":92.14,"high":93.9899,"low":88.8,"amount":55806650.970812,"amplitude":0.054613,"askPrice":90.89,"askSize":101,"bidPrice":90.71,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-3.597465,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1772226000000},"marketStatusCode":2,"adr":0,"listingDate":1597982400000,"exchange":"NASDAQ","adjPreClose":95.03,"preHourTrading":{"tag":"盘前","latestPrice":91.94,"preClose":95.03,"latestTime":"09:29 EST","volume":691,"amount":63591.27199,"timestamp":1772202599999,"change":-3.09,"changeRate":-0.032516,"amplitude":0.042723},"postHourTrading":{"tag":"盘后","latestPrice":94.75,"preClose":95.03,"latestTime":"19:20 EST","volume":150499,"amount":14301813.148,"timestamp":1772151628979,"change":-0.28,"changeRate":-0.002946,"amplitude":0.002946},"volumeRatio":0.680752,"impliedVol":0.6169,"impliedVolPercentile":0.1992},"requestUrl":"/m/hq/s/KYMR","defaultTab":"news","newsList":[{"id":"1104281611","title":"异动解读 | 强劲财报与充足现金储备提振信心，Kymera Therapeutics盘中大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104281611","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104281611?lang=zh_cn&edition=full","pubTime":"2026-02-27 04:55","pubTimestamp":1772139313,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc.（KYMR）今日盘中股价大幅上涨5.04%，市场表现活跃。消息面上，公司于盘前正式公布了2025年第四季度及全年财务业绩，并同步更新了业务进展。报告显示，公司财务状况稳健，截至2025年12月31日，持有的现金储备高达16亿美元。这一充足的资金为其未来的研发和运营提供了坚实保障，预计足以支持公司各项业务推进至2029年。强劲的财务表现和充裕的现金状况，有效增强了投资者对公司长期发展潜力的信心，从而推动了股价在交易时段的显著上扬。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KYMR"],"gpt_icon":0},{"id":"1171937452","title":"异动解读 | 股东拟出售3139万股，Kymera Therapeutics盘前大跌7.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171937452","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171937452?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:28","pubTimestamp":1772112516,"startTime":"0","endTime":"0","summary":"生物技术公司Kymera Therapeutics, Inc.今日盘前股价大幅下挫7.88%，引起了市场的广泛关注。消息面上，根据美国证券交易委员会披露的文件显示，Kymera Therapeutics的部分现有股东计划出售总计3139万股公司普通股。此类由股东发起的售股行为将增加市场中的股票供应量，通常被视为潜在的利空信号，可能引发投资者对公司股票未来走势的担忧，从而导致股价承压下跌。需要指出的是，此次售股由公司股东发起，而非公司发行新股，因此Kymera Therapeutics公司自身不会从此次售股中获得任何收益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KYMR"],"gpt_icon":0},{"id":"1155188159","title":"Kymera Therapeutics公司 - 股东拟出售3139万股普通股 - 美国证监会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1155188159","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155188159?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:27","pubTimestamp":1772112453,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件显示，生物技术公司Kymera Therapeutics, Inc. 的部分现有股东计划出售总计3139万股公司普通股。\n此次售股行为由公司股东发起，而非公司发行新股，因此Kymera Therapeutics公司自身不会从此次售股中获得任何收益。此类股东减持行为通常会引起市场对公司股票未来供应量及股价潜在波动的关注。投资者需密切关注后续市场动态及相关公告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"1131455532","title":"Kymera Therapeutics, Inc. 财务状况稳健：截至2025年12月31日持有16亿美元现金，资金可支撑至2029年","url":"https://stock-news.laohu8.com/highlight/detail?id=1131455532","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131455532?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:18","pubTimestamp":1772108303,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. 展现出强劲的财务实力。截至2025年12月31日，公司持有的现金储备高达16亿美元。这一充足的资金为其未来的研发和运营提供了坚实保障，预计足以支持公司各项业务推进至2029年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"1146980037","title":"Kymera Therapeutics公布2025年第四季度及全年财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1146980037","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146980037?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:13","pubTimestamp":1772108026,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc.（简称\"Kymera Therapeutics\"）近日正式披露了其2025年第四季度及全年的财务报告，同时向市场通报了公司最新的业务动态。此次公布涵盖了公司在关键财务指标上的表现，以及研发管线、战略合作等方面的进展，为投资者提供了全面的运营概览。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"1143087468","title":"Kymera Therapeutics宣布首例患者完成KT-621给药——首创口服Stat6降解剂进入Breadth二期B阶段哮喘临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1143087468","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143087468?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:01","pubTimestamp":1769688060,"startTime":"0","endTime":"0","summary":"生物技术公司Kymera Therapeutics宣布，其创新药物KT-621已完成针对哮喘患者的首例给药，标志着该口服Stat6降解剂正式进入Breadth二期B阶段临床试验。作为同类首创疗法，KT-621通过靶向降解Stat6蛋白来调节免疫反应，为中重度哮喘患者提供潜在治疗选择。此次临床试验旨在评估KT-621的安全性、耐受性及有效性，预计将纳入多国临床研究中心的重症哮喘患者。该阶段试验数据的收集与分析，将为后续全球临床开发策略提供关键依据。Stat6信号通路在过敏性炎症疾病中扮演核心角色。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"gpt_icon":0},{"id":"1104376733","title":"Kymera Therapeutics Inc. 计划于2026年推进至少一款首创口服免疫学项目的新开发候选药物进入IND阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1104376733","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104376733?lang=zh_cn&edition=full","pubTime":"2026-01-13 20:07","pubTimestamp":1768306058,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics Inc. 近日公布了其研发管线的重要规划，公司计划在2026年前推进至少一款针对首创（First-in-Class）口服免疫学项目的新开发候选药物，旨在向新药临床试验申请（IND）阶段迈进。这一战略部署凸显了公司致力于在免疫治疗领域开拓创新疗法的决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"1194110609","title":"Kymera Therapeutics开展的皮炎治疗试验取得了积极进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1194110609","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194110609?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:40","pubTimestamp":1765197643,"startTime":"0","endTime":"0","summary":"实现了深度STAT6降解。","market":"us","thumbnail":"https://static.tigerbbs.com/08ecfd9eac9c3137da2cc8b5e8e15cc0","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/08ecfd9eac9c3137da2cc8b5e8e15cc0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"131f4a8ae97812e1f16587f8e011d27b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Kymera Therapeutics开展的皮炎治疗试验取得了积极进展","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR"],"gpt_icon":0},{"id":"1194478362","title":"盘前｜CFLT、KYMR暴涨，CoreWeave“跳水”，特斯拉跌超1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194478362","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194478362?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:27","pubTimestamp":1765196866,"startTime":"0","endTime":"0","summary":"美股三大指数期货在盘前交易时段小幅上涨。","market":"us","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CFLT","KYMR","CVNA"],"gpt_icon":1},{"id":"1153788539","title":"Kymera Therapeutics, Inc. - 在KT-621治疗中观察到所有疾病终点的强健临床活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1153788539","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153788539?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:07","pubTimestamp":1765195631,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. - 在KT-621治疗中观察到所有疾病终点的强健临床活性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"131f4a8ae97812e1f16587f8e011d27b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"gpt_icon":0},{"id":"1118432812","title":"Kymera Therapeutics Inc - KT-621 Broaden2 II期B试验针对严重的阿尔茨海默病仍在进行中，数据预计于2027年中公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1118432812","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118432812?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:04","pubTimestamp":1765195482,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics Inc - KT-621 Broaden2 II期B试验针对严重的阿尔茨海默病仍在进行中，数据预计于2027年中公布","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"1191653930","title":"Kymera Therapeutics公布KT-621的第一阶段B临床试验取得积极结果，该药为首个口服Stat6降解剂，适用于中重度特应性皮炎患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1191653930","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191653930?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:03","pubTimestamp":1765195430,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics公布KT-621的第一阶段B临床试验取得积极结果，该药为首个口服Stat6降解剂，适用于中重度特应性皮炎患者","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"131f4a8ae97812e1f16587f8e011d27b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"1143730690","title":"Kymera Therapeutics将在2025年12月8日公布KT-621扩展1B期特应性皮炎试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1143730690","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143730690?lang=zh_cn&edition=full","pubTime":"2025-12-06 05:02","pubTimestamp":1764968524,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics将在2025年12月8日公布KT-621扩展1B期特应性皮炎试验结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"gpt_icon":0},{"id":"1129014922","title":"Kymera Therapeutics首位患者在Broaden2 II期B临床试验中接受KT-621治疗，这是一种首创的口服Stat6降解剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1129014922","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129014922?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:02","pubTimestamp":1764072160,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics首位患者在Broaden2 II期B特应性皮炎临床试验中接受KT-621治疗，这是一种首创的口服Stat6降解剂","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"gpt_icon":0},{"id":"1184658612","title":"Kymera Therapeutics宣布将在欧洲皮肤病与性病学会及欧洲呼吸学会大会上发表关于首创口服Stat6降解剂KT-621的最新口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1184658612","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184658612?lang=zh_cn&edition=full","pubTime":"2025-09-17 19:01","pubTimestamp":1758106914,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics宣布将在欧洲皮肤病与性病学会及欧洲呼吸学会大会上发表关于首创口服Stat6降解剂KT-621的最新口头报告","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"gpt_icon":0},{"id":"2517437281","title":"Kymera Therapeutics, Inc.2024财年实现净利润-2.24亿美元，同比减少52.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517437281","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517437281?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363235,"startTime":"0","endTime":"0","summary":"3月8日，Kymera Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-2.24亿美元，同比减少52.38%；其中营业收入为47.07百万美元，同比减少40.11%，每股基本收益为-2.98美元。从资产负债表来看，Kymera Therapeutics, Inc.总负债1.42亿美元，其中短期债务13.11百万美元，资产负债比为6.89，流动比率为0.08。机构评级：截至2025年3月8日，当前有17家机构对Kymera Therapeutics, Inc.目标价做出预测，其中目标均价为58.82美元，其中最低目标价为41.00美元，最高目标价为97.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000043abed65dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000043abed65dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KYMR"],"gpt_icon":0},{"id":"1147904941","title":"异动解读 | Kymera Therapeutics第四季度业绩逊预期 盘中股价大跌7.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=1147904941","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147904941?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:10","pubTimestamp":1740669010,"startTime":"0","endTime":"0","summary":"生物技术公司Kymera Therapeutics今日盘中股价大幅下跌7.27%,引发市场广泛关注。据统计,截至收盘KYMR报33.34美元,成交量3.18万股,振幅4.84%。公司最新公布的2024年第四季度财报显示,KYMR当季每股亏损0.88美元,远高于华尔街分析师预期的0.78美元亏损。与去年同期相比,营收更是大幅下滑84.56%。显而易见,Kymera Therapeutics业绩大幅逊于市场预期,给投资者带来了较大的不确定性和失望。公司财务数据的疲软表现,可能是导致KYMR股价今日大跌的主要诱因之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | Kymera Therapeutics第四季度业绩逊预期 盘中股价大跌7.27%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KYMR"],"gpt_icon":0},{"id":"2514385542","title":"Kymera Therapeutics, Inc.盘中异动 早盘大幅跳水5.71%报33.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385542","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514385542?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:40","pubTimestamp":1740667238,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时40分，Kymera Therapeutics, Inc.股票出现异动，股价大幅下跌5.71%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.69%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224039a2567cac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224039a2567cac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KYMR","LENZ"],"gpt_icon":0},{"id":"1121089825","title":"Kymera Therapeutics 2024年Q4 GAAP每股收益$(0.88)不及预期$(0.78)，销售额$739万不及预期$1182万","url":"https://stock-news.laohu8.com/highlight/detail?id=1121089825","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121089825?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:07","pubTimestamp":1740658067,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics报告季度每股亏损$，比分析师的共识预期$低12.82%。与去年同期每股亏损$相比，这是252%的下降。以上内容来自Benzinga Earnings专栏，原文如下：Kymera $Therapeutics$  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 12.82 percent. This is a 252 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $7.39 million which missed the analyst consensus estimate of $11.82 million by 37.45 percent.  This is a 84.56 percent decrease over sale","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","LENZ"],"gpt_icon":0},{"id":"2510803663","title":"Kymera Therapeutics, Inc.盘中异动 早盘快速下挫5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510803663","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510803663?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:41","pubTimestamp":1739284909,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时41分，Kymera Therapeutics, Inc.股票出现异动，股价大幅下挫5.13%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.30%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112241499881bf20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112241499881bf20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","KYMR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kymeratx.com","stockEarnings":[{"period":"1week","weight":0.0986},{"period":"1month","weight":0.3171},{"period":"3month","weight":0.4},{"period":"6month","weight":1.3066},{"period":"1year","weight":1.6875},{"period":"ytd","weight":0.2213}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0089},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.1594},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kymera Therapeutics, Inc.，一家根据特拉华州法律于2017年5月25日成立的有限责任公司。该公司是一家生物制药公司，致力于发现和开发新颖的小分子疗法，该疗法可通过利用药物选择性地降解致病蛋白。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.060685},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.006255},{"month":3,"riseRate":0.2,"avgChangeRate":-0.073393},{"month":4,"riseRate":0.6,"avgChangeRate":0.013164},{"month":5,"riseRate":0.2,"avgChangeRate":-0.147131},{"month":6,"riseRate":0.6,"avgChangeRate":0.114241},{"month":7,"riseRate":0.8,"avgChangeRate":0.172329},{"month":8,"riseRate":0.6,"avgChangeRate":0.035263},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.031798},{"month":10,"riseRate":0.666667,"avgChangeRate":0.069597},{"month":11,"riseRate":0.666667,"avgChangeRate":0.180891},{"month":12,"riseRate":0.666667,"avgChangeRate":0.094258}],"exchange":"NASDAQ","name":"Kymera Therapeutics, Inc.","nameEN":"Kymera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kymera Therapeutics, Inc.(KYMR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kymera Therapeutics, Inc.(KYMR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kymera Therapeutics, Inc.,KYMR,Kymera Therapeutics, Inc.股票,Kymera Therapeutics, Inc.股票老虎,Kymera Therapeutics, Inc.股票老虎国际,Kymera Therapeutics, Inc.行情,Kymera Therapeutics, Inc.股票行情,Kymera Therapeutics, Inc.股价,Kymera Therapeutics, Inc.股市,Kymera Therapeutics, Inc.股票价格,Kymera Therapeutics, Inc.股票交易,Kymera Therapeutics, Inc.股票购买,Kymera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kymera Therapeutics, Inc.(KYMR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kymera Therapeutics, Inc.(KYMR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}